Home > Rheumatology > ACR 2019 > Late-Breaking Abstracts > Corticosteroid therapy in GCA: higher platelets – lower relapse rate

Corticosteroid therapy in GCA: higher platelets – lower relapse rate

Presented By
Dr Samuel Deshayes, Hospital Center University Of Caen Normandie, France
Conference
ACR 2019
An increased platelet count and a GLCCI1 gene polymorphism were shown to be associated with a lower relapse rate in patients with giant cell arteritis (GCA) treated with corticosteroids [1]. Corticosteroids are the cornerstone in the management of GCA, the most common cause of primary vasculitis in adults. However, approximately half of the patients will relapse, and up to 86% develop steroid-induced adverse events. In this study, risk factors for relapse in GCA patients treated with prednisolone were assessed. All included patients were steroid-naïve with a diagnosis of GCA. Patients received steroids, with a 10 to 16 months predefined tapering schedule and a planned follow-up of 18 months after inclusion. Genotyping of glucocorticoid-induced transcript 1 (GLCCI1) promoter polymorphism (rs37972), which regulates steroid-induced apoptosis, and prednisolone clearance were performed between 14 and 28 days of treatment. Among t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on